Open AccessPrimary hepatic diffuse large B-cell lymphoma with favorable response to immunochemotherapy
Author(s) -
NaiWen Kang,
YuHsuan Kuo,
HungChang Wu,
Wei-Yu Chen,
ChinTe Huang,
ShihSung Chuang,
YinHsun Feng
Publication year - 2017
Publication title -
journal of cancer research and practice
Language(s) - English
Resource type - Journals
eISSN - 2589-0425
pISSN - 2311-3006
DOI - 10.1016/j.jcrpr.2017.07.004
Subject(s) - medicine , lymphoma , malignancy , biopsy , chemotherapy , rituximab , bone marrow , lymph , liver biopsy , non hodgkin's lymphoma , pathology , gastroenterology , oncology
Primary hepatic lymphoma (PHL) is a tumor confined to the liver without involvement of the spleen, lymph nodes, or bone marrow. It is an extremely rare malignancy, accounting for only 0.0016% of non-Hodgkin lymphoma worldwide. Generally, a liver biopsy is required to make a diagnosis of PHL due to the lack of specific clinical manifestations, biochemical indicators, and image features. However, there is currently a lack of consensus on the standard treatment of PHL. Chemotherapy can be an effective treatment due to the tumor's chemosensitivity. Herein, we report a 78-year-old male with a confirmed diagnosis of primary hepatic diffuse large B-cell lymphoma via liver biopsy. We treated the patient with immunochemotherapy using Rituximab-COP combination. The tumor had a favorable response, without recurrence for over a three-year period of follow-up. Even though the reported median survival of PHL is 15 months, appropriate treatment can provide a chance for sustained remission